NW Bio Exhibit Will Describe DCVax Technology and Clinical Trial Progress at Annual Meeting of Over 25,000 Oncologists

BETHESDA, Md., May 23, 2013 — Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for solid tumor
cancers, announced today that it will use its exhibit at this
year’s American Society Of Clinical Oncology (ASCO) meeting in
Chicago to highlight its leadership role in immune
therapy. 

The ASCO annual meeting is the pre-eminent conference focused on
clinical treatment of cancer, with attendance of more than 25,000
oncologists and other medical professionals from across the US and
all over the world.  The 49th annual meeting of ASCO will be
held at the McCormick Place Convention Center in Chicago from May
31 to June 4, 2013.

NW Bio will be participating in the ASCO meeting with a 400
square foot exhibit, located adjacent to the Industry Experts
Theater in the Exhibit Hall.  NW Bio’s exhibit will include
space for private meetings as well as information about the
Company’s promising DCVax immune therapy platform for all solid
tumor cancers, and the Company’s multiple clinical trial
programs. 

“ASCO presents a unique opportunity to reach oncologists from
throughout the US and around the world with the latest information
about our broad DCVax technology for personalized immune therapy
treatments for all solid tumor cancers,” commented Linda Powers, NW
Bio CEO.  “Immune therapies have become an area of rapidly
growing interest among oncologists, and NW Bio is strongly
positioned at the forefront of this emerging new treatment
category, with two product lines already at the Phase III clinical
trial stage and a third product line at the Phase I/II trial
stage.  We look forward to raising awareness of our DCVax
technology and products with a major exhibit at this year’s ASCO
meeting.”

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both the
United States and Europe.  The Company has a broad platform
technology for DCVax dendritic cell-based vaccines.  The
Company’s lead program is a 312-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM).  GBM is the most
aggressive and lethal form of brain cancer.  The Company also
previously received clearance from the FDA for a 612-patient Phase
III trial in prostate cancer, and clearance from the FDA for Phase
I/II trials in multiple other cancers.  The Company also
conducted a Phase I/II trial with DCVax for metastatic ovarian
cancer together with the University of Pennsylvania. 

Disclaimer

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995.  Words such as “expect,” “believe,”
“intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and
similar expressions are intended to identify forward-looking
statements.  Actual results may differ materially from those
projected in any forward-looking statement.  Specifically,
there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the
Company’s ability to raise additional capital, risks related to the
Company’s ability to enroll patients in its clinical trials and
complete the trials on a timely basis, the uncertainty of the
clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company’s products will
demonstrate safety and efficacy.  Additional information on
these and other factors, including Risk Factors, which could affect
the Company’s results, is included in its Securities and Exchange
Commission (“SEC”) filings.  Finally, there may be other
factors not mentioned above or included in the Company’s SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement.  You should
not place undue reliance on any forward-looking statements. 
The Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.